Meloxicam synergistically enhances the in vitro effects of sunitinib malate on bladder-cancer cells

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Applied Biomedicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2478/V10136-012-0034-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugs.

  2012cited by this paper
• Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance?

  2012cited by this paper
• Disparities in bladder cancer.

  2012cited by this paper
• Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.

  2012cited by this paper
• The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.

  2011cited by this paper
• From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine Tumors

  2011cited by this paper
• Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation

  2011cited by this paper
• The age of biomedicine: current trends in traditional subjects

  2011cited by this paper
• Sunitinib Malate Synergistically Potentiates Anti-Tumor Effect of Gemcitabine in Human Bladder Cancer Cells

  2011cited by this paper
• Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

  2011cited by this paper
• Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.

  2010cited by this paper
• Phase II study of sunitinib in patients with metastatic urothelial cancer.

  2010cited by this paper
• Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system.

  2010cited by this paper
• Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells

  2010cited by this paper
• Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract

  2010cited by this paper
• Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells.

  2010cited by this paper
• Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.

  2009cited by this paper
• Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

  2009cited by this paper
• Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study

  2008cited by this paper
• The comet assay: topical issues.

  2008cited by this paper
• Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells

  2008cited by this paper
• Chronic inflammation and bladder cancer.

  2007cited by this paper
• SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation.

  2007cited by this paper
• Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells.

  2007cited by this paper
• In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells.

  2006cited by this paper
• Nuclear factor-κB in cancer development and progression

  2006cited by this paper
• The role of autophagy in cancer development and response to therapy

  2005cited by this paper
• Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters.

  2005cited by this paper
• Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells

  2005cited by this paper
• Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography.

  2005cited by this paper
• Autophagy: in sickness and in health.

  2004cited by this paper
• Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice.

  2004cited by this paper
• Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

  2004cited by this paper
• The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?

  2004cited by this paper
• Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.

  2004cited by this paper
• The comet assay for DNA damage and repair

  2004influential reference
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  2003cited by this paper
• COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression

  2002cited by this paper
• A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation.

  2001cited by this paper
• Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.

  2000influential reference
• Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma

  2000cited by this paper
• The role of cyclooxygenases in inflammation, cancer, and development

  1999cited by this paper
• Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.

  1999cited by this paper
• Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.

  1998cited by this paper
• Meloxicam inhibits the growth of colorectal cancer cells.

  1998cited by this paper
• Meloxicam: selective COX-2 inhibition in clinical practice.

  1997cited by this paper
• Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

  1994cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines.

  2017cites this paper
• Meloxicam increases intracellular accumulation of doxorubicin via downregulation of multidrug resistance-associated protein 1 (MRP1) in A549 cells.

  2015cites this paper
• Effects of Naproxen on Cell Proliferation and Genotoxicity in MG-63 Osteosarcoma Cell Line

  2014cites this paper
• In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer.

  2013cites this paper
• Synergistic Effect between Cisplatin and Sunitinib Malate on Human Urinary Bladder-Cancer Cell Lines

  2013cites this paper